Treatment of Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma: liver resection versus TACE and beyond

Huo, Ya Ruth; Xiang, Hao; Chan, Michael Vinchill

doi:10.21037/atm-20-4903

Ann Transl Med

2020

DOI: 10.21037/atm-20-4903

|View full text |Cite

Treatment of Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma: liver resection versus TACE and beyond

Ya Ruth Huo¹,

Hao Xiang²,

Michael Vinchill Chan³

Abstract: Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo)+ bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2020;38:476.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Efficacy of Sodium Alginate Microsphere Interventional Embolization Combined with Sorafenib in Advanced Hepatocellular Carcinoma

Wang

2023

j biomed nanotechnol

View full text Add to dashboard Cite

To explore the efficacy of sodium alginate microsphere (SAM) transcatheter arterial chemoembolization (TACE) combined with sorafenib in liver cancer (LC), 118 patients with advanced LC were enrolled in the study. Patients were randomized into c-TACE and SAM-TACE groups; in addition to TACE, the SAM-TACE group was treated with SAM and oral sorafenib. The physical properties and cytotoxicity of SAM were investigated in vitro. Liver function, tumor markers, the extent of solid tumor remission, adverse events, and survival rates were compared between the two groups during a 2-year follow-up period. The diameter of SAM was approximately 180–250 μm and the swelling rate of the microspheres was good, especially at pH 7.4. SAMs did not reduce 3T3-L1 and ECV-304 cell activities and was biocompatible. SAM-TACE was effective in protecting liver function in patients and, when combined with sorafenib, reduced tumor marker levels and cancer volumes, resulting in improved patient survival rates. SAM-TACE combined with sorafenib did not increase the rate of adverse reactions. Therefore, SAM-TACE combined with sorafenib has great potential in the treatment of advanced LC.

show abstract

Efficacy of Sodium Alginate Microsphere Interventional Embolization Combined with Sorafenib in Advanced Hepatocellular Carcinoma

Wang

2023

j biomed nanotechnol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Treatment of Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma: liver resection versus TACE and beyond

Abstract: Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo)+ bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2020;38:476.

Cited by 1 publication

References 24 publications

Efficacy of Sodium Alginate Microsphere Interventional Embolization Combined with Sorafenib in Advanced Hepatocellular Carcinoma

Efficacy of Sodium Alginate Microsphere Interventional Embolization Combined with Sorafenib in Advanced Hepatocellular Carcinoma

Contact Info

Product

Resources

About